Angiotensin-converting enzyme (ACE) can be elevated in some people with sarcoidosis, but it is not specific and cannot confirm or exclude the disease by itself. Doctors interpret ACE together with symptoms, imaging and other tests. ACE should not be used alone to start or change treatment. Ask your clinician what the result means in your individual situation.
ACE phenotyping may help identify systemic sarcoidosis
The technique measures ACE activity originating in different tissues rather than only total blood levels
Marisa Wexler, MS: avatar
Marisa Wexler, MS | 14 October 2022
Clinical researchers proposed a new type of biochemical analysis called ACE phenotyping that may help diagnose sarcoidosis involvement outside the lungs.
A new type of biochemical analysis called ACE phenotyping may help diagnose sarcoidosis involvement outside the lungs, a study suggests.
“We believe that our method enables noninvasive detection of patients with systemic sarcoidosis,” the researchers wrote.
A feature of sarcoidosis is the formation of clusters of inflammatory cells called granulomas in the organs of the body. The lungs are most commonly affected, in which case it is called pulmonary sarcoidosis, but many organs can be affected at the same time, which is called systemic sarcoidosis.
!!!!! Determining the exact extent of disease involvement is important for providing appropriate care !!!!!
The enzyme ACE (angiotensin-converting enzyme) is normally present in many tissues and in granulomas associated with sarcoidosis. It plays an important role in regulating blood pressure. The report notes that, although elevated ACE levels are common in sarcoidosis, previous research found that simply measuring these levels was not a useful sarcoidosis biomarker because they did not reflect disease activity.
Depending on where it is made, the ACE enzyme has a slightly different shape because of small differences in the sugar molecules attached to the protein chain.
Over three decades of studying the protein, a team of scientists from the United States and Russia produced numerous antibodies that can bind specifically to ACE originating from a particular tissue. Using these antibodies, the researchers proposed a new analytical strategy called ACE phenotyping or ACE fingerprinting.
ACE from immune cells offers clues
The method involves measuring total ACE activity using standardised enzyme assays and then using antibodies to determine the proportions of the ACE enzyme originating in different tissues of the body.
Most ACE in the blood normally originates in the lungs. The researchers proposed that an increased proportion of ACE from immune cells might indicate sarcoidosis activity outside the lungs. They emphasised that this method examines the proportions of ACE from different tissues rather than total enzyme levels in the blood.
The researchers wrote that the main limitation of serum (blood) ACE measurement as a valid biomarker for sarcoidosis was that ACE levels can be elevated in other disease processes. They said their new ACE fingerprinting approach helped address this problem.
As a proof of concept, the researchers analysed blood samples from 20 patients at a pulmonary clinic. On the basis of the ACE phenotype, eight had findings suggestive of sarcoidosis outside the lungs. PET scans in two of them confirmed sarcoidosis-like inflammation outside the lungs.
The researchers also noted a patient with high ACE levels whose ACE phenotyping results did not suggest sarcoidosis. This patient was ultimately found to have hyperthyroidism.
The researchers wrote that this example showed the potential of the approach to rule out systemic sarcoidosis despite elevated ACE levels. They described the possibility of ruling out extrapulmonary organ involvement with a relatively noninvasive test that was less expensive than a PET scan as a significant clinical advance.
In the final set of tests, the scientists analysed blood ACE in 68 people diagnosed with sarcoidosis. Although these patients generally had higher ACE levels than people without the disease, ACE phenotyping showed no significant difference between those with and without clear clinical signs of involvement outside the lungs.
The researchers speculated that ACE phenotyping might identify extrapulmonary involvement only after granuloma formation had exceeded a certain threshold of disease burden. They said more research into this potential biomarker was needed.
The researchers said ACE phenotyping had the potential to add significant value very early in the assessment of patients with suspected sarcoidosis. If its usefulness and accuracy were confirmed in additional studies, they proposed adding it to the sarcoidosis assessment algorithm as early as the first clinical visit at which sarcoidosis was suspected.
Author: Marisa Wexler, MS
Source: https://sarcoidosisnews.com/news/diagnosing-systemic-sarcoidosis-may-be-aided-with-ace-phenotyping/
ACE enzyme values
ACE: angiotensin-converting enzyme
Reference interval in the cited source: 16–68. Reference ranges depend on the laboratory, method and sample; this range is not universal.
The source reports elevated serum ACE levels in 40% of patients with sarcoidosis, depending on time since diagnosis, acute or chronic disease, extent of disease, radiological stage and many other factors. Elevated ACE values are not specific to sarcoidosis.
Elevated values may occur, for example, with the development of a liver lesion.
Correlation between elevated ACE and granulomas
Serum ACE (angiotensin-converting enzyme) levels in patients with sarcoidosis and typical or atypical HRCT manifestations
Shahram Kahkouee, Katayoon Samadi, [...] and Lida Rezaiian
Sarcoidosis is an inflammatory disease involving multiple organs. Before the widespread use of computed tomography (CT), its severity was assessed using chest X-ray abnormalities. HRCT can distinguish active inflammatory changes from irreversible fibrosis. In this study, the researchers analysed ACE levels in 148 patients diagnosed with sarcoidosis.
The patients were categorised by their HRCT results into four groups: 1) patients diagnosed with chronic disease; 2) patients diagnosed with non-chronic disease; 3) patients with typical HRCT changes; and 4) patients with atypical HRCT changes. The mean ACE level in each group was then calculated and compared.
HRCT scans of patients with chronic sarcoidosis showed more atypical sarcoidosis patterns. There was also an inverse correlation between chronicity and ACE level (P-value <0.05).
The study described HRCT as another modality that could be useful when the diagnosis of sarcoidosis was not definitive.
MeSH keywords: Angiotensin-converting enzyme inhibitors, four-dimensional computed tomography, sarcoidosis
Sarcoidosis is an inflammatory disease of unknown origin that involves multiple organs and is associated with noncaseating epithelioid granulomas and lymphocytic alveolitis.
The article reports that the hilar and mediastinal lymph nodes and lung parenchyma are affected in 90% of patients with sarcoidosis.
Although pulmonary and constitutional symptoms predominate, the article reports that 50% of these patients are asymptomatic and are diagnosed unexpectedly after abnormalities are found on chest X-rays.
Before the widespread use of computed tomography (CT), the severity of sarcoidosis was categorised on the basis of chest X-ray abnormalities. CT scans, particularly high-resolution computed tomography (HRCT), are highly effective in detecting minor abnormalities of the lung parenchyma in the early stages of sarcoidosis. HRCT can also distinguish active inflammatory changes from irreversible fibrosis. For example, findings such as parenchymal nodules, ground-glass opacities and alveolar opacities indicate granulomatous inflammation that is usually reversible after treatment. In contrast, abnormalities such as honeycombing, bulla formation and thick septal bronchiectasis indicate irreversible fibrosis.
Typical sarcoidosis.
Serum biomarkers can provide supporting information in the assessment of sarcoidosis, but they do not establish the diagnosis on their own. Diagnosis is based on a comprehensive clinical assessment and, where needed, histopathological findings and exclusion of other possible causes.
One difficulty in diagnosing sarcoidosis from a pathological sample is the similarity of its pathological appearance to that of other granulomatous diseases that can also have high ACE levels. The article therefore describes finding a relationship between the radiological disease pattern and ACE level as valuable when ACE levels and pathological analysis are inconclusive.
In this study, the researchers analysed ACE levels in 148 patients diagnosed with sarcoidosis. They categorised the patients by their HRCT results into four groups: 1) patients diagnosed with chronic disease; 2) patients diagnosed with non-chronic disease; 3) patients with typical HRCT changes; and 4) patients with atypical HRCT changes.
Materials and methods
The study examined the hospital or clinical records of 148 patients diagnosed with sarcoidosis according to the guidelines of the European Respiratory Society, American Thoracic Society and World Association of Sarcoidosis and Other Granulomatous Disorders. These patients had been referred to Masih Daneshvari Hospital in Tehran, Iran, between 2011 and 2014. They were patients in the pulmonary department or patients referred to outpatient clinics for follow-up. Written informed consent was obtained from all patients.
All patients had sarcoidosis with pulmonary involvement. Patients were excluded if they smoked, had a concomitant chronic fibrotic lung disease such as hypersensitivity pneumonitis or interstitial lung disease, or had another systemic disease that increases ACE levels, such as chronic obstructive pulmonary disease, lung cancer or nephrotic syndrome.
Patient information, including age, sex and the most recent ACE level, was recorded. Two experts assessed the HRCT scans by consensus. Abnormalities such as honeycombing, bulla formation and traction bronchiectasis in fibrotic bands usually indicate chronic disease, so patients with these abnormalities were placed in the chronic group. Patients whose scans showed reversible changes such as parenchymal nodules, ground-glass opacities and alveolar opacities were placed in the non-chronic group.
Symmetrical prehilar and mediastinal lymphadenopathy and perilymphatic micronodules were considered typical sarcoidosis changes (Figure 3), while macronodules, a pulmonary mass, miliary opacities and linear opacities were considered atypical manifestations (Figure 1). The mean ACE level of each group was then calculated and compared.
Statistical analysis
Statistical analysis was performed using SPSS software, version 18. Descriptive analysis was used to present quantitative variables as the mean (standard deviation) and categorical variables as frequencies (%). Categorical data were compared using the chi-square test. A value below 0.05 was considered statistically significant.
Results
The study included 148 patients with sarcoidosis. Their mean age was 46 years (standard deviation 16), with a range of 17–75 years. There were 86 women (58%) and 62 men (42%). The mean ACE level was 68 U/L (standard deviation 15), with a range of 3–259.
As shown in Table 1, patients were categorised by chronicity, typical or atypical changes, and ACE level. ACE levels were divided into two groups using 50 U/L as the cutoff.
Categorisation of patients by ACE level and HRCT appearance.
Among 127 patients with non-chronic disease, 82 (65%) had typical HRCT manifestations of sarcoidosis. Among 21 patients with chronic disease, only seven (33%) had typical HRCT appearances. This relationship between HRCT manifestation and disease chronicity was statistically significant (P=0.007).
Correlation of ACE level with disease chronicity and typical or atypical HRCT appearance.
Discussion
The study assessed ACE levels and HRCT scans in 148 patients with sarcoidosis. The results showed an association between disease chronicity and HRCT patterns. Scans of patients with chronic sarcoidosis showed more atypical sarcoidosis patterns. There was also an inverse correlation between chronicity and ACE level. No statistically significant difference between typical and atypical HRCT appearances was found on the basis of the patients’ ACE levels.
Serum ACE may be elevated in some people with sarcoidosis and in other conditions. The test has limited sensitivity and specificity and does not reliably indicate total granuloma burden. ACE is interpreted alongside the clinical picture and other findings; on its own, it neither confirms nor excludes sarcoidosis.
The article describes KI-6 and sIL-2R as two other serum markers that are mostly increased in patients with higher radiographic stages of sarcoidosis. It also describes these markers as particularly indicative of disease progression and changes in lymphocytic alveolitis.
The article reports that researchers found no correlation between ACE level and sarcoidosis prognosis [22].
Other studies analysing increased ACE levels in other granulomatous and non-granulomatous diseases reported sensitivity of 40%–100% and specificity of 83%–99% for this marker in diagnosing sarcoidosis [24, 25]. No differences in ACE levels were reported between the sexes or between age groups [26, 27]. The article states that many studies found more severe sarcoidosis in patients with higher ACE levels. Silverstein and colleagues found an inverse relationship between sarcoidosis chronicity and ACE level, which the authors of this study also observed.
In this retrospective study, some patients’ last measurement was taken during prednisolone treatment, which is a limitation of the analysis. Corticosteroids can affect ACE levels, so the doctor takes treatment into account when interpreting the result. Do not stop or change prednisolone or any other prescribed treatment for an ACE measurement without discussing it with your doctor.
Conclusions
The study found that sarcoidosis chronicity, as assessed from the patients’ HRCT appearances, was inversely proportional to ACE levels. The authors considered this another diagnostic clue in patients whose ACE levels and pathological analyses were inconclusive.
Polish Journal of Radiology
Termedia publishing